Tiragolumab Impresses in Multiple Trials, PMID: 32576590
ASCO 2020 non-small lung cancer (NSCLC) personal highlights, PMID: 33456617
Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting, PMID: 33271494
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity, PMID: 33670993
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. PMID: 31500665
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity. PMID: 33670993
TIGIT checkpoint inhibition for myeloma. PMID: 30337318
PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes. PMID: 33408249
Enhanced expression of TIGIT but not neuropilin-1 in patients with type 2 diabetes mellitus. PMID: 32540486
Human TIGIT on porcine aortic endothelial cells suppresses xenogeneic macrophage-mediated cytotoxicity. PMID: 31402149
TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells. PMID: 32028328
Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. PMID: 33303760
Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. PMID: 33000173
The Inhibitory PVRL1/PVR/TIGIT Axis in Immune Therapy for Hepatocellular Carcinoma. PMID: 32574623
A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. PMID: 32887749
Recovery of CD226-TIGIT(+)FoxP3(+) and CD226-TIGIT-FoxP3(+) regulatory T cells contributes to clinical remission from active stage in ulcerative colitis patients. PMID: 31883787
TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. PMID: 31376919
TOX is a critical regulator of tumour-specific T cell differentiation. PMID: 31207604
Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ gammadelta T Cells in AML Patients. PMID: 32802845
DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. PMID: 30081950
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. PMID: 31611702
Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis. PMID: 32793241
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. PMID: 32503945
Expression of the immune checkpoint receptor TIGIT in seminoma. PMID: 31423216
CD226 opposes TIGIT to disrupt Tregs in melanoma. PMID: 30046006
The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. PMID: 28035916
Dysfunctional role of elevated TIGIT expression on T cells in oral squamous cell carcinoma patients. PMID: 33125794
Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. PMID: 32269065
Targeting NK-cell checkpoints for cancer immunotherapy. PMID: 28236750
Checkpoint Receptor TIGIT Expressed on Tim-1(+) B Cells Regulates Tissue Inflammation. PMID: 32668241
Effective Anti-tumor Response by TIGIT Blockade Associated With FcgammaR Engagement and Myeloid Cell Activation. PMID: 33117369
NK Cell Dysfunction and Checkpoint Immunotherapy. PMID: 31552017
[Study on role of TIGIT signal in Th1/Th2 balance in Schistosoma japonicum-infected mice]. PMID: 29770653
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. PMID: 30132062
TIGIT(+) A2Ar-Dependent anti-uveitic Treg cells are a novel subset of Tregs associated with resolution of autoimmune uveitis. PMID: 32201225
TIGIT expression levels on CD4+ T cells are correlated with disease severity in patients with psoriasis. PMID: 29512851
Antibody engineers seek optimal drug targeting TIGIT checkpoint. PMID: 32887966
TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells. PMID: 29960041
Tiragolumab Impresses in Multiple Trials. PMID: 32576590
Control of Regulatory T Cells by Co-signal Molecules. PMID: 31758535
Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. PMID: 33413573
Balancing natural killer cell activation through paired receptors. PMID: 25743219
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. PMID: 30659053
CD155, an onco-immunologic molecule in human tumors. PMID: 28730595
Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy., PMID:40374899
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study., PMID:40147985
Staphylococcus aureus-specific TIGIT+ Treg are present in the blood of healthy subjects - a hurdle for vaccination?, PMID:39981298
Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target Engagement., PMID:39921877
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study., PMID:39855251
Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates., PMID:39297961
The efficacy and safety of immunotherapy as first-line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data., PMID:39026980
IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma., PMID:38861301
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)., PMID:38858106
Implementation of a Three-Way Comparability Assessment for a Bioanalytical Anti-Drug Antibody Method., PMID:38637446
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis., PMID:38623838
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study., PMID:38614072
Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors., PMID:38556530
Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab., PMID:38460520
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors., PMID:38451273
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells., PMID:38418879
Targeting TIGIT for cancer immunotherapy: recent advances and future directions., PMID:38229100
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors., PMID:38206370
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)., PMID:38105505
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer., PMID:37976444
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer., PMID:37946136
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial., PMID:37768658
Acute liver failure following immune checkpoint inhibitors., PMID:37660741
Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis., PMID:37435087
Anti-TIGIT therapies for solid tumors: a systematic review., PMID:36933320
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno., PMID:36636263
Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer., PMID:35654050
Tiragolumab Results Cast Shadow on TIGIT Pipeline., PMID:35652612
Tiragolumab active in PD-L1+ NSCLC., PMID:35606416
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study., PMID:35576957
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer., PMID:35292828
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity., PMID:33670993
ASCO 2020 non-small lung cancer (NSCLC) personal highlights., PMID:33456617
Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting., PMID:33271494
Tiragolumab Impresses in Multiple Trials., PMID:32576590
For research use only. Not for human or drug use.
